Understanding the Complexities and Interdependencies that Deliver Successful Outcomes. As the industry moves to a patient-centric, value-based care model, stakeholders across the continuum of care are focused on creating systems and solutions that put the patient…
A Conversation with Pharmaceutical Commerce & Jim Lang, Chief Executive Officer, EVERSANA Not quite a year ago, an assemblage of pharma service providers came into being as EVERSANA. Funded by two private equity firms with a…
Why Product Launches Can’t Be Distracted By Empty Promises. We can all agree that innovations in therapeutic development have advanced beyond traditional product launch strategies and service models. In every step of the product lifecycle, we…
Market Access Macrotrends provides insight for you to stay on top of market access trends, anticipate how the healthcare landscape is evolving, and provide strategic guidance for your organization. Market Access Macrotrends answers your questions about changes in…
In this September feature, PM360 dives into what it takes to create relationships and experiences with and for patients. Considering that patients want more authentic interactions when dealing with life sciences companies, Jenny Sparano, director of…
With more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals suffering from a rare disease, regenerative medicine holds the hope for a cure – transforming healthcare by revolutionizing patient care from…
Compliance is a broad and extremely important area in almost every industry and more so in life sciences as it directly and indirectly impacts patient lives. Because the life science industry is continuously evolving, we are…
In this September feature, PM360 asked experts for insight into the changes that need to happen to create better experiences for patients and ultimately serve them better. Kathi Henson, Chief Patient Service Officer, shares insight into…
In the September Think Tank, PM360 asks patients and experts at agencies and life sciences companies to share their best co-creation solutions in developing successful patient-centric strategies. Nicole Pitaniello, Managing Director of Client Services at the…
The pharmaceutical industry is complex. A litany of companies and brands are competing for top-of-mind usage with clinicians, a cohesive partnership with payers, and active engagement with patients. It’s hard enough to bring a drug to…
Enacted in 1992, the 340B Drug Pricing Program was intended to stretch scarce federal resources and services to more eligible patients. Despite achieving this goal in many respects, it has also become notoriously difficult to manage…